These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
502 related articles for article (PubMed ID: 33276780)
1. Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma. Ishii T; Ito T; Sumiyoshi S; Ogiso S; Fukumitsu K; Seo S; Taura K; Uemoto S World J Surg Oncol; 2020 Dec; 18(1):319. PubMed ID: 33276780 [TBL] [Abstract][Full Text] [Related]
2. The Dominant Component and Clinicopathological Characteristics of Combined Hepatocellular-cholangiocarcinoma After Radical Resection. Matsubara K; Kobayashi T; Tadokoro T; Namba Y; Fukuhara S; Oshita KO; Honmyo N; Kuroda S; Arihiro K; Ohdan H Anticancer Res; 2024 Oct; 44(10):4551-4559. PubMed ID: 39348996 [TBL] [Abstract][Full Text] [Related]
3. Clinicopathological features and prognosis of combined hepatocellular carcinoma and cholangiocarcinoma after surgery. Lee SD; Park SJ; Han SS; Kim SH; Kim YK; Lee SA; Ko YH; Hong EK Hepatobiliary Pancreat Dis Int; 2014 Dec; 13(6):594-601. PubMed ID: 25475861 [TBL] [Abstract][Full Text] [Related]
4. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification. Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585 [TBL] [Abstract][Full Text] [Related]
5. Clinical features and outcomes of combined hepatocellular carcinoma and cholangiocarcinoma versus hepatocellular carcinoma versus cholangiocarcinoma after surgical resection: a propensity score matching analysis. Lin CW; Wu TC; Lin HY; Hung CM; Hsieh PM; Yeh JH; Hsiao P; Huang YL; Li YC; Wang YC; Shu CW; Chen YS BMC Gastroenterol; 2021 Jan; 21(1):20. PubMed ID: 33413162 [TBL] [Abstract][Full Text] [Related]
6. Radiological features and outcomes of combined hepatocellular-cholangiocarcinoma in patients undergoing surgical resection. Chi CT; Chau GY; Lee RC; Chen YY; Lei HJ; Hou MC; Chao Y; Huang YH J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):125-133. PubMed ID: 30876788 [TBL] [Abstract][Full Text] [Related]
7. Combined hepatocellular-cholangiocarcinoma and its mimickers: Diagnostic pitfalls in surgical pathology. Laohawetwanit T; Lerttanatum N; Wanpiyarat N; Manasilp N; Chaiparnich S Ann Diagn Pathol; 2021 Aug; 53():151770. PubMed ID: 34147845 [TBL] [Abstract][Full Text] [Related]
8. Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis. Yagi N; Suzuki T; Mizuno S; Kojima M; Kudo M; Sugimoto M; Kobayashi S; Gotohda N; Ishii G; Nakatsura T Cancer Sci; 2022 May; 113(5):1564-1574. PubMed ID: 35226764 [TBL] [Abstract][Full Text] [Related]
9. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA. Wang C; Chen C; Hu W; Tao L; Chen J Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206 [TBL] [Abstract][Full Text] [Related]
10. Postresection Outcomes of Combined Hepatocellular Carcinoma-Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Yoon YI; Hwang S; Lee YJ; Kim KH; Ahn CS; Moon DB; Ha TY; Song GW; Jung DH; Lee JW; Hong SM; Yu ES; Lee SG J Gastrointest Surg; 2016 Feb; 20(2):411-20. PubMed ID: 26628072 [TBL] [Abstract][Full Text] [Related]
11. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma? Sasaki M; Sato Y; Nakanuma Y Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959 [TBL] [Abstract][Full Text] [Related]
12. Longterm prognosis of combined hepatocellular carcinoma-cholangiocarcinoma following liver transplantation and resection. Jung DH; Hwang S; Song GW; Ahn CS; Moon DB; Kim KH; Ha TY; Park GC; Hong SM; Kim WJ; Kang WH; Kim SH; Yu ES; Lee SG Liver Transpl; 2017 Mar; 23(3):330-341. PubMed ID: 28027599 [TBL] [Abstract][Full Text] [Related]
13. Post-resection prognosis of combined hepatocellular carcinoma-cholangiocarcinoma cannot be predicted by the 2019 World Health Organization classification. Kim M; Hwang S; Ahn CS; Kim KH; Moon DB; Song GW; Jung DH; Hong SM Asian J Surg; 2021 Nov; 44(11):1389-1395. PubMed ID: 33766528 [TBL] [Abstract][Full Text] [Related]
14. Combined hepatocellular-cholangiocarcinoma: which preoperative clinical data and conventional MRI characteristics have value for the prediction of microvascular invasion and clinical significance? Wang X; Wang W; Ma X; Lu X; Li S; Zeng M; Xu K; Yang C Eur Radiol; 2020 Oct; 30(10):5337-5347. PubMed ID: 32385649 [TBL] [Abstract][Full Text] [Related]
16. Clinical, diagnostic, and pathologic features and surgical outcomes of combined hepatocellular-cholangiocarcinoma in dogs: 14 cases (2009-2021). Terai K; Ishigaki K; Kagawa Y; Okada K; Yoshida O; Sakurai N; Heishima T; Asano K J Am Vet Med Assoc; 2022 Apr; 260(13):1668-1674. PubMed ID: 35482569 [TBL] [Abstract][Full Text] [Related]
17. Clinical and pathological features of Allen's type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma. Tang D; Nagano H; Nakamura M; Wada H; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Dono K; Monden M J Gastrointest Surg; 2006; 10(7):987-98. PubMed ID: 16843869 [TBL] [Abstract][Full Text] [Related]
18. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis. Tang Y; Wang L; Teng F; Zhang T; Zhao Y; Chen Z Int J Med Sci; 2021; 18(1):187-198. PubMed ID: 33390787 [No Abstract] [Full Text] [Related]
19. Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma. Zuo HQ; Yan LN; Zeng Y; Yang JY; Luo HZ; Liu JW; Zhou LX Hepatobiliary Pancreat Dis Int; 2007 Apr; 6(2):161-5. PubMed ID: 17374575 [TBL] [Abstract][Full Text] [Related]
20. How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI? Lee HS; Kim MJ; An C Eur Radiol; 2019 May; 29(5):2408-2416. PubMed ID: 30552477 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]